For research and educational purposes only. Not medical advice.

GLOW Reference

Educational, not medical advice reference for GLOW: Recovery, Skin/Hair; regulatory status, evidence posture, source review, and schedule notes.…

Plain English

What it is
GLOW is a nickname for a mixed peptide product, not a single approved drug. It puts three lab-made peptides in one vial: GHK-Cu (a tiny copper-carrying protein the body makes on its own), plus BPC-157 and TB-500. It is sold for research and is not an approved medicine.
What people use it for
People reach for GLOW hoping for two things at once: nicer skin and hair from the GHK-Cu part, and faster healing of tendons, joints, and soft tissue from the BPC-157 and TB-500 part. This is based on personal stories in peptide communities, not on approved medical directions.
What the science shows
No study has ever tested these three peptides together, so the blend itself is unproven. On their own, GHK-Cu has its best evidence in skin creams and lab-skin tests rather than as a shot, while BPC-157 and TB-500 come almost entirely from animal studies. Solid human proof is missing.
The catch
Nothing here is FDA-approved. BPC-157 and TB-500 are flagged in FDA reviews of pharmacy-compounded peptides, and BPC-157 is banned for athletes. Because GHK-Cu carries copper, it can be risky for people with copper-handling problems such as Wilson's disease or a copper allergy. Mixed research vials also have no quality checks, so what is actually inside can vary.

Reference summary

There are no published studies of GLOW as a combination; all evidence is per ingredient and does not test the three peptides together. GHK-Cu has the strongest support in topical and ex vivo human-skin and animal wound-healing work, not injectable human trials. BPC-157 is dominated by preclinical rodent injury-healing studies with only a handful of small human pilot reports, and a 2025 peer-reviewed narrative review still classes it as investigational. TB-500 evidence is largely extrapolated from full-length thymosin beta-4 animal studies rather than direct human TB-500 trials.

Regulatory and posture

Categories
Recovery, Skin/Hair
Aliases
GLOW, GLOW blend, GLOW peptide blend, GHK-Cu BPC-157 TB-500 blend, GHK-Cu + BPC-157 + TB-500
Evidence posture
preclinical - No studies test GLOW as a blend. Per-ingredient evidence is thin: GHK-Cu is strongest topically, BPC-157 is mostly animal data, and TB-500 leans on thymosin beta-4 extrapolation.
Regulatory status
No FDA-approved drug label exists for the GLOW blend or for its individual ingredients. GLOW is a community name for a research-only combination of GHK-Cu, BPC-157, and TB-500; the blend itself has never been reviewed or approved by any regulator. FDA placed BPC-157 (acetate and arginate salt forms) in Category 2 of the 503A interim bulk drug substances list on September 29, 2023, meaning it is not permitted for use in section 503A pharmacy compounding. On April 16, 2026, FDA published a Federal Register notice (docket FDA-2025-N-6895) scheduling a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to consider BPC-157 and TB-500, along with KPV and MOTS-c, for the 503A Bulks List; pending that review neither is permitted for 503A compounding. BPC-157 is prohibited for athletes under the WADA S0 non-approved substances category. GHK-Cu is sold as a low-concentration cosmetic ingredient, but that cosmetic posture does not transfer to injectable use.
Content review status
research reference

Selected public sources

Related tools